TY - JOUR
T1 - Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis
AU - Trenkwalder, Teresa
AU - Nelson, Christopher P.
AU - Musameh, Muntaser D.
AU - Mordi, Ify R.
AU - Kessler, Thorsten
AU - Pellegrini, Costanza
AU - Debiec, Radoslaw
AU - Rheude, Tobias
AU - Lazovic, Viktor
AU - Zeng, Lingyao
AU - Martinsson, Andreas
AU - Gustav Smith, J.
AU - Gådin, Jesper R.
AU - Franco-Cereceda, Anders
AU - Eriksson, Per
AU - Nielsen, Jonas B.
AU - Graham, Sarah E.
AU - Willer, Cristen J.
AU - Hveem, Kristian
AU - Kastrati, Adnan
AU - Braund, Peter S.
AU - Palmer, Colin N. A.
AU - Aracil, Amparo
AU - Husser, Oliver
AU - Koenig, Wolfgang
AU - Schunkert, Heribert
AU - Lang, Chim C.
AU - Hengstenberg, Christian
AU - Samani, Nilesh J.
N1 - Collection and genotyping of the GeneCAST Leicester cohorts were supported by the Leicester NIHR Biomedical Centre. NJS and CPN are funded by the British Heart Foundation and NJS is a NIHR Senior Investigator. IRM is supported by a NHS Education for Scotland/Chief Scientist Office Postdoctoral Clinical Lectureship [grant number: PCL17/07]. CCL acknowledges support from the British Heart Foundation [grant numbers: PG/16/32/32132 and PG/14/4/30539]. JGS was supported by the European Research Council, Swedish Heart-Lung Foundation, the Wallenberg Center for Molecular Medicine at Lund University, the Swedish Research Council, the Crafoord Foundation, governmental funding of clinical research within the Swedish National Health Service, Skåne University Hospital in Lund, and the Scania county.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Background: Aortic valve stenosis (AVS) and coronary artery disease (CAD) have a significant genetic contribution and commonly co-exist. To compare and contrast genetic determinants of the two diseases, we investigated associations of the LPA and 9p21 loci, i.e. the two strongest CAD risk loci, with risk of AVS. Methods: We genotyped the CAD-associated variants at the LPA (rs10455872) and 9p21 loci (rs1333049) in the GeneCAST (Genetics of Calcific Aortic STenosis) Consortium and conducted a meta-analysis for their association with AVS. Cases and controls were stratified by CAD status. External validation of findings was undertaken in five cohorts including 7,880 cases and 851,152 controls. Results: In the meta-analysis including 4,651 cases and 8,231 controls the CAD-associated allele at the LPA locus was associated with increased risk of AVS (OR 1.37; 95%CI 1.24-1.52, p=6.9x10-10) with a larger effect size in those without CAD (OR 1.53; 95%CI 1.31-1.79) compared to those with CAD (OR 1.27; 95%CI 1.12-1.45). The CAD-associated allele at 9p21 was associated with a trend towards lower risk of AVS (OR 0.93; 95%CI 0.88-0.99, p=0.014). External validation confirmed the association of the LPA risk allele with risk of AVS (OR 1.37; 95%CI 1.27-1.47), again with a higher effect size in those without CAD. The small protective effect of the 9p21 CAD risk allele could not be replicated (OR 0.98; 95%CI 0.95-1.02).Conclusions: Our study confirms the association of the LPA locus with risk of AVS, with a higher effect in those without concomitant CAD. Overall, 9p21 was not associated with AVS.
AB - Background: Aortic valve stenosis (AVS) and coronary artery disease (CAD) have a significant genetic contribution and commonly co-exist. To compare and contrast genetic determinants of the two diseases, we investigated associations of the LPA and 9p21 loci, i.e. the two strongest CAD risk loci, with risk of AVS. Methods: We genotyped the CAD-associated variants at the LPA (rs10455872) and 9p21 loci (rs1333049) in the GeneCAST (Genetics of Calcific Aortic STenosis) Consortium and conducted a meta-analysis for their association with AVS. Cases and controls were stratified by CAD status. External validation of findings was undertaken in five cohorts including 7,880 cases and 851,152 controls. Results: In the meta-analysis including 4,651 cases and 8,231 controls the CAD-associated allele at the LPA locus was associated with increased risk of AVS (OR 1.37; 95%CI 1.24-1.52, p=6.9x10-10) with a larger effect size in those without CAD (OR 1.53; 95%CI 1.31-1.79) compared to those with CAD (OR 1.27; 95%CI 1.12-1.45). The CAD-associated allele at 9p21 was associated with a trend towards lower risk of AVS (OR 0.93; 95%CI 0.88-0.99, p=0.014). External validation confirmed the association of the LPA risk allele with risk of AVS (OR 1.37; 95%CI 1.27-1.47), again with a higher effect size in those without CAD. The small protective effect of the 9p21 CAD risk allele could not be replicated (OR 0.98; 95%CI 0.95-1.02).Conclusions: Our study confirms the association of the LPA locus with risk of AVS, with a higher effect in those without concomitant CAD. Overall, 9p21 was not associated with AVS.
KW - 9p21
KW - Aortic valve stenosis
KW - Lipoprotein (a)
KW - Risk factors
KW - Valvular heart disease
KW - Chromosomes, Human, Pair 9/genetics
KW - Humans
KW - Middle Aged
KW - Lipoprotein(a)/genetics
KW - Aortic Valve Stenosis/diagnosis
KW - Genetic Predisposition to Disease/genetics
KW - Male
KW - Genetic Variation/genetics
KW - Case-Control Studies
KW - Coronary Artery Disease/diagnosis
KW - Polymorphism, Single Nucleotide/genetics
KW - Genome-Wide Association Study/methods
KW - Female
KW - Genetic Loci/genetics
KW - Aged
UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85057002644&origin=inward&txGid=26d98cd5f80a75d4f2279bdba8d9c2dd
U2 - 10.1016/j.ijcard.2018.11.094
DO - 10.1016/j.ijcard.2018.11.094
M3 - Article
C2 - 30482443
AN - SCOPUS:85057002644
SN - 0167-5273
VL - 276
SP - 212
EP - 217
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -